In NEJM this week, researchers in the US and Europe report on the effects of MEK inhibitors on the survival of patients with BRAF-mutated melanoma. The team randomly assigned 322 patients with BRAF V600E or V600K metastatic melanoma to receive either the oral selective MEK inhibitor trametinib, or chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.